Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.58
-1.29 (-18.78%)
At close: Dec 5, 2025, 4:00 PM EST
5.59
+0.01 (0.15%)
After-hours: Dec 5, 2025, 7:59 PM EST
Protara Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Protara Therapeutics stock have an average target of 20.33, with a low estimate of 12 and a high estimate of 23. The average target predicts an increase of 264.34% from the current stock price of 5.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protara Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +312.19% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +312.19% | Nov 19, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +276.34% | May 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +312.19% | Apr 28, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $12 | Buy | Initiates | $12 | +115.05% | Apr 16, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.30
from -2.17
EPS Next Year
-1.42
from -1.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.16 | -1.25 | ||||
| Avg | -1.30 | -1.42 | ||||
| Low | -1.33 | -1.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.